Supprelin LA

Central Precocious Puberty

Supprelin LA is specifically indicated for the treatment of children with central precocious puberty (CPP). This condition occurs when a child's body begins changing into that of an adult too soon.

Signs of Early Puberty

Healthcare providers may prescribe this medication when signs of puberty appear earlier than expected, typically:

• Before age 8 in girls.
• Before age 9 in boys.

Goals of Treatment

The primary purpose of using Supprelin LA is to temporarily suppress the hormones that trigger early puberty. This helps to:

• Slow or stop the development of secondary sexual characteristics, such as breast development or the growth of pubic and underarm hair.
• Manage the rate of bone maturation, which can help ensure the child reaches a more typical adult height, as early puberty can cause bones to stop growing too soon.

The medication is delivered through a small implant placed under the skin of the inner upper arm, where it releases medicine continuously over a long period.

Mechanism of Action

Supprelin LA contains histrelin, which acts like a natural hormone in the body called gonadotropin-releasing hormone (GnRH). Under normal conditions, GnRH is released in pulses to tell the pituitary gland to produce other hormones that trigger puberty. However, the Supprelin LA implant provides a continuous, steady release of the medication.

Hormone Regulation

When the body receives a constant supply of this medication instead of natural pulses, the pituitary gland eventually stops responding to GnRH. This process leads to a significant decrease in the production of two key hormones:

• Luteinizing hormone (LH)
• Follicle-stimulating hormone (FSH)

Because these hormones are responsible for signaling the ovaries to produce estrogen or the testes to produce testosterone, their reduction causes sex hormone levels to drop to those typically seen in children before puberty begins.

Effects on Early Puberty

By maintaining low levels of sex hormones, Supprelin LA helps to:

• Slow down or stop the development of secondary sexual characteristics, such as breast development or the growth of pubic hair.
• Slow the rapid bone maturation that occurs during early puberty, which can help children reach a more typical adult height.

During the first week or two of treatment, there may be a temporary increase in hormone levels before they begin to decline. This is a normal part of how the medication starts to work.

Common Side Effects

The most frequent side effects associated with Supprelin LA involve reactions at the site where the implant is placed. These may include pain, redness, bruising, swelling, or itching. Other common side effects include:

• Initial symptom flare: A temporary worsening of puberty symptoms, such as vaginal bleeding or breast enlargement in girls, typically occurring during the first month of treatment.
• Headache.
• Weight gain.
• Breast tenderness.
• Mood swings or irritability.

Serious Side Effects

While less common, some side effects can be serious. Seek medical attention immediately for the following:

• Psychiatric symptoms: New or worsening depression, aggression, anxiety, or suicidal thoughts.
• Neurological symptoms: Seizures or signs of increased pressure in the brain (pseudotumor cerebri), which may cause severe headaches, dizziness, nausea, or vision changes like blurred or double vision.
• Allergic reactions: Hives, skin rash, or swelling of the face, lips, and throat.
• Implant complications: Signs of infection at the site, or if the implant breaks, moves, or protrudes through the skin. If the implant cannot be felt under the skin, specialized imaging may be required to locate it for removal.

Pregnancy and Fetal Harm

Supprelin LA is contraindicated for use during pregnancy. The medication can cause harm to a developing fetus or result in pregnancy loss. It is important to confirm that a patient is not pregnant before the implant is inserted.

Psychiatric and Neurological Risks

• Psychiatric Events: Some patients may experience emotional changes, including irritability, impatience, anger, and aggression.
• Seizures: There is a risk of seizures, particularly in individuals with a history of epilepsy, brain anomalies, or those taking medications that increase seizure risk.
• Pseudotumor Cerebri: This condition involves increased pressure within the skull. Symptoms to monitor include headaches, nausea, and vision changes such as double vision or blurred vision.

Initial Hormone Surge

During the first week after insertion, there is a temporary increase in sex hormone levels. This may cause a brief worsening of puberty symptoms, such as light vaginal bleeding or breast enlargement in girls.

Implant Site Reactions

The insertion and removal of the implant can cause local reactions like pain, bruising, or swelling. In some cases, the implant may break or be difficult to locate for removal.

Monitoring

Healthcare providers monitor growth velocity and bone age throughout treatment to ensure the medication is working as intended.

Pregnancy

Supprelin LA is contraindicated for use during pregnancy. Clinical data indicates that the medication may cause harm to a developing fetus. Healthcare providers typically perform a pregnancy test before starting treatment to ensure the patient is not pregnant. If pregnancy is suspected or occurs during treatment, the medication should be discontinued and a healthcare provider should be notified immediately.

Patients of childbearing potential should use effective non-hormonal contraception while receiving this medication. Hormonal contraceptives are generally not recommended as they may interfere with the effectiveness of the treatment.

Breastfeeding

It is currently unknown if histrelin, the active ingredient in Supprelin LA, passes into human breast milk. Because of the potential for serious adverse reactions in a nursing infant, a decision must be made whether to stop breastfeeding or to stop using the medication. Patients should discuss the risks and benefits with their healthcare provider to determine the best course of action based on their specific situation.

Available Forms

Supprelin LA is supplied in the following form:

• Subcutaneous Implant: A small, flexible, non-biodegradable reservoir designed for insertion under the skin.

Design and Delivery

The implant is a sterile, diffusion-controlled system that is surgically placed by a healthcare professional, usually in the inner upper arm. It is designed to maintain a consistent level of medication in the body for an extended duration. Once the treatment period has ended, the implant is removed and can be replaced if further treatment is required.

FDA Approval and Indications

Supprelin LA (histrelin acetate) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of children with central precocious puberty (CPP). CPP is a condition characterized by the early onset of sexual development, typically occurring before age 8 in girls and age 9 in boys.

Safety Communications and Labeling Updates

The FDA monitors the safety of Supprelin LA through the FDA Adverse Event Reporting System (FAERS). In 2017, the FDA identified a potential signal of serious risk regarding pseudotumor cerebri, also known as idiopathic intracranial hypertension, associated with the use of gonadotropin-releasing hormone (GnRH) agonists. This class of drugs includes histrelin acetate.

Following a safety review, the FDA required updates to the prescribing information for GnRH agonist products to include warnings about the risk of idiopathic intracranial hypertension. Symptoms of this condition may include headache, blurred vision, or loss of vision.

Regulatory Status and Administration

Supprelin LA is regulated as a prescription-only medication. It is not available for self-administration and must be surgically inserted and removed by a healthcare provider. The implant is designed to provide continuous delivery of the medication for a 12-month period, after which it must be replaced or removed.

Factors Influencing Cost

Several factors determine the overall expense of treatment with Supprelin LA:

• The Medication: The cost of the histrelin implant itself.
• Surgical Procedures: Because the implant must be placed and removed by a healthcare professional, there are costs associated with the minor surgical procedures performed in a clinical setting.
• Frequency: The implant is designed to provide continuous medication for 12 months, meaning these costs typically occur on an annual basis.

Insurance and Financial Assistance

Supprelin LA is often covered under a patient's medical insurance benefit rather than a standard pharmacy benefit because it is administered by a physician. Coverage levels vary significantly depending on the specific insurance plan.

Patients and caregivers may find financial support through:

• Manufacturer-sponsored patient assistance programs.
• Co-pay assistance programs for eligible patients with commercial insurance.
• Specialty pharmacy services that help navigate insurance approvals and billing.

It is recommended to contact the insurance provider and the healthcare facility's billing department in advance to understand the out-of-pocket costs and any prior authorization requirements.